MedTrace Logo

Umbilical Cord Blood Therapy for Global Developmental Delay

NCT01769716 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-01-23

No results posted yet for this study

Summary

This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic umbilical cord blood therapy for children with global developmental delay.

Conditions

  • Global Developmental Delay

Interventions

PROCEDURE

Umbilical cord blood transplantation

Sponsors & Collaborators

  • CHA University

    collaborator OTHER

  • MinYoung Kim, M.D.

    lead OTHER

Principal Investigators

  • MinYoung Kim, M.D., Ph.D. · CHA University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769716 on ClinicalTrials.gov